Literature DB >> 23070085

Farnesoid X receptor regulates vascular reactivity through nitric oxide mechanism.

R Zhang1, H-H Ran, Y-X Zhang, P Liu, C-Y Lu, Q Xu, Y Huang.   

Abstract

Farnesoid X receptor (FXR), a ligand-activated transcription factor and a member of nuclear receptor family, is not only highly expressed in the adrenal cortex, intestine, kidney and liver, but also has recently been found in the vasculature. However, the evidence on the roles of FXR in the vasculature is limited and whether FXR regulates vascular reactivity is poorly understood. In present study, we investigated the expression of FXR protein in rat vasculature by immunohistochemical method and tested the effects of FXR activation by chenodeoxycholic acid (CDCA) on thoracic aortic contraction and dilation. We also detected the level of nitrite/nitrate (NOx) and superoxide in the thoracic aortic segments. We found that FXR was expressed in rat carotid arteries, thoracic aorta, abdominal aorta and femoral arteries. FXR activation by CDCA significantly (P<0.01) inhibited the contractile responses of rat thoracic aorta rings to KCl and phenylephrine. The cumulative concentrations of CDCA caused a concentration-dependent relaxation, which could be partly impaired by L-NAME, an inhibitor of nitric oxide (NO) synthase. The NOx content in thoracic aorta significantly (P<0.01) increased when treated with CDCA. Meanwhile, the vascular redox status was not altered by high concentration of CDCA. The present study suggested that FXR regulated vascular reactivity through NO mechanism, which merits further attention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070085

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  6 in total

1.  Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model.

Authors:  Sang Youb Han; Hye Kyoung Song; Jin Joo Cha; Jee Young Han; Young Sun Kang; Dae Ryong Cha
Journal:  Acta Diabetol       Date:  2021-01-05       Impact factor: 4.280

2.  Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.

Authors:  Leonardo A Moraes; Amanda J Unsworth; Jonathan M Gibbins; Sakthivel Vaiyapuri; Marfoua S Ali; Parvathy Sasikumar; Tanya Sage; Gagan D Flora; Alex P Bye; Neline Kriek; Emilie Dorchies; Olivier Molendi-Coste; David Dombrowicz; Bart Staels; David Bishop-Bailey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-06       Impact factor: 8.311

3.  Comparative in vitro effects of calcineurin inhibitors on functional vascular relaxations of both rat thoracic and abdominal aorta.

Authors:  Ashok Jadhav; Venkat Gopalakrishnan; Ahmed Shoker
Journal:  Adv Pharmacol Sci       Date:  2013-06-18

4.  Evidence for the involvement of FXR signaling in ovarian granulosa cell function.

Authors:  Kentaro Takae; Mizuho Nakata; Takafumi Watanabe; Hiroshi Sasada; Hiroshi Fujii; Ikuo Tomioka
Journal:  J Reprod Dev       Date:  2018-11-16       Impact factor: 2.214

5.  The effect of omega- 3 polyunsaturated fatty acids on endothelial tight junction occludin expression in rat aorta during lipopolysaccharide-induced inflammation.

Authors:  Jakub Krizak; Karel Frimmel; Iveta Bernatova; Jana Navarova; Ruzena Sotnikova; Ludmila Okruhlicova
Journal:  Iran J Basic Med Sci       Date:  2016-03       Impact factor: 2.699

6.  The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury.

Authors:  Andrea Ferrigno; Laura Giuseppina Di Pasqua; Clarissa Berardo; Veronica Siciliano; Vittoria Rizzo; Luciano Adorini; Plinio Richelmi; Mariapia Vairetti
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.